- Home
- ADXN vs LYRA Comparison
ADXN vs LYRA Comparison
Compare ADXN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- LYRA
- Stock Information
- Founded
- ADXN 2002
- LYRA 2005
- Country
- ADXN Switzerland
- LYRA United States
- Employees
- ADXN N/A
- LYRA N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- ADXN Health Care
- LYRA Health Care
- Exchange
- ADXN Nasdaq
- LYRA Nasdaq
- Market Cap
- ADXN 8.1M
- LYRA 7.6M
- IPO Year
- ADXN N/A
- LYRA 2020
- Fundamental
- Price
- ADXN $8.81
- LYRA $3.98
- Analyst Decision
- ADXN
- LYRA Hold
- Analyst Count
- ADXN 0
- LYRA 1
- Target Price
- ADXN N/A
- LYRA $16.00
- AVG Volume (30 Days)
- ADXN 22.2K
- LYRA 25.4K
- Earning Date
- ADXN 11-10-2025
- LYRA 11-07-2025
- Dividend Yield
- ADXN N/A
- LYRA N/A
- EPS Growth
- ADXN N/A
- LYRA N/A
- EPS
- ADXN N/A
- LYRA N/A
- Revenue
- ADXN $210,347.00
- LYRA $770,000.00
- Revenue This Year
- ADXN $86.57
- LYRA N/A
- Revenue Next Year
- ADXN N/A
- LYRA $106.28
- P/E Ratio
- ADXN N/A
- LYRA N/A
- Revenue Growth
- ADXN N/A
- LYRA N/A
- 52 Week Low
- ADXN $6.51
- LYRA $3.81
- 52 Week High
- ADXN $12.05
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- ADXN 47.70
- LYRA 20.99
- Support Level
- ADXN $8.50
- LYRA $5.40
- Resistance Level
- ADXN $9.00
- LYRA $4.80
- Average True Range (ATR)
- ADXN 0.50
- LYRA 0.43
- MACD
- ADXN -0.09
- LYRA -0.20
- Stochastic Oscillator
- ADXN 20.95
- LYRA 0.38
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.